c ebpβ-lip Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer | Journal of Experimental & Clinical Cancer Research C/EBP beta Antibody | Cell
C EBP beta Antibody Cell Signaling Technology Continuous Activation of C EBP Transcription Factor Prevents Fibrosis Resolution After Alcohol Cessation Cellular and Molecular Gastroenterology and Hepatology c ebp lip drug Increasing intratumor C EBP LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer Journal of Experimental & Clinical Cancer Research A screening strategy for IFN and Mediated JCPyV Suppression through C EBP LIP Isoform Inhibition of C EBP activity by LIP expression inhibits the induction Download Scientific Diagram
Pay in 4 interest-free payments of $6.58 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12


